COVID-19最新消息
由于受新冠疫情的影响,北京很多区域和地方都受到封控,很多人员要求居家办公。这对我们的提货和派送产生了很大的影响。为了保障我们的服务水平,我们正在制定相应的应对措施。如需更多信息,请联系我们的客服部。

Extensive packaging inventory, backed by data through our Climate Engineering and Optimisation labs.

FiercePharma

With the advent of cell and gene therapies, getting those treatments to the right patients at the right time requires both manufacturers and suppliers to offer the most reliable and timely logistics possible. With the FDA projecting it will likely approve as many as 10 to 20 cell and gene therapies every year by 2025, the stakes are being raised to get new treatments to market. As many of those new therapies are based on an individual’s own cells, patients themselves have become a key part of the new supply chain.

Read the article to learn more about how cell and gene therapies will continue to develop over the coming years.